Profile data is unavailable for this security.
About the company
Bavarian Nordic A/S is a Denmark-based biotechnology company engaged in the development, production and marketing of vaccines for the treatment of cancer and infectious diseases. The Company’s drug pipeline comprises two areas: Cancer Immunotherapy and Infectious Disease. The Cancer Immunotherapy pipeline is focused on: prostate cancer, including PROSTVAC and Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) PRO; breast cancer, providing CV-301 breast and MVA-BN HER2 vaccines; and colorectal cancer, offering CV-301 colon. The Infectious Disease pipeline produces vaccines for a range of illnesses, such as smallpox, anthrax, filoviruses, foot-and-mouth diseases and respiratory syncytial virus. The Company is a parent of Bavarian Nordic GmbH, BN Infectious Diseases A/S, and Bavarian Nordic Inc, among others.
- Revenue in DKK (TTM)2.40bn
- Net income in DKK-599.24m
- Incorporated1992
- Employees917.00
- LocationBavarian Nordic A/SPhilip Heymans Alle 3HELLERUP 2900DenmarkDNK
- Websitehttps://www.bavarian-nordic.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bonesupport Holding AB | 195.30m | -48.88m | 3.73bn | 92.00 | -- | 19.66 | -- | 19.12 | -1.12 | -1.12 | 4.46 | 4.33 | 0.8058 | 0.5543 | 6.40 | 3,119,554.00 | -20.17 | -35.30 | -24.45 | -44.57 | 89.94 | 87.87 | -25.03 | -84.28 | 3.86 | -65.33 | 0.0611 | -- | 17.71 | 15.27 | 15.66 | -- | 19.98 | -- |
| Calliditas Therapeutics AB | 275.61m | -431.71m | 3.90bn | 169.00 | -- | 7.11 | -- | 14.15 | -12.18 | -12.18 | 7.73 | 13.63 | 0.2497 | 25.16 | 3.34 | 6,136,621.00 | -39.13 | -31.46 | -44.45 | -34.68 | 90.49 | -- | -156.69 | -288.51 | 4.42 | -- | 0.3916 | -- | 26,141.08 | -- | -15.41 | -- | 145.12 | -- |
| Swedencare AB (publ) | 1.08bn | 63.22m | 3.98bn | 506.00 | 71.49 | 0.7335 | 16.87 | 3.68 | 0.5173 | 0.5173 | 10.79 | 50.41 | 0.2263 | 2.43 | 9.23 | 5,680,857.00 | 1.32 | 4.78 | 1.35 | 5.07 | 51.50 | 57.82 | 5.84 | 11.94 | 2.46 | -521.07 | 0.1866 | 32.49 | 221.77 | 70.46 | 63.76 | 41.06 | -- | -- |
| Surgical Science Sweden AB | 510.45m | 94.14m | 5.54bn | 233.00 | 50.50 | 1.87 | 42.50 | 10.85 | 3.17 | 3.17 | 15.74 | 85.75 | 0.174 | 1.88 | 6.02 | 3,589,120.00 | 3.21 | 3.41 | 3.40 | 3.67 | 66.87 | 78.80 | 18.44 | 15.42 | 2.34 | 34.85 | 0.0428 | 0.00 | 249.98 | 47.90 | 452.66 | 92.43 | 4.25 | -- |
| Nykode Therapeutics ASA | 250.50m | -139.93m | 5.69bn | 147.00 | -- | 4.81 | -- | 22.72 | -0.6136 | -0.6136 | 1.16 | 5.72 | 0.1642 | -- | 5.40 | 3,446,915.00 | -9.17 | 25.30 | -10.28 | 27.55 | -- | -- | -55.86 | 46.19 | -- | -- | 0.03 | -- | -84.20 | 311.05 | -106.29 | -- | 157.24 | -- |
| BioGaia AB | 704.87m | 185.51m | 5.79bn | 195.00 | 32.41 | 4.78 | 28.85 | 8.22 | 2.70 | 2.70 | 10.26 | 18.31 | 0.5017 | -- | -- | 6,202,617.00 | 13.20 | 18.70 | 14.16 | 21.27 | 72.69 | 74.18 | 26.32 | 26.20 | -- | -- | 0.00 | 75.30 | 5.09 | 7.99 | 9.20 | 4.22 | 2.60 | -0.6484 |
| AddLife AB | 6.05bn | 405.98m | 9.50bn | 2.20k | 24.33 | 3.01 | 10.99 | 1.57 | 4.87 | 4.87 | 72.64 | 39.40 | 0.7693 | 3.96 | 6.52 | 4,932,631.00 | 5.18 | 9.03 | 8.48 | 17.10 | 37.61 | 35.74 | 6.73 | 7.57 | 0.4418 | 6.13 | 0.5417 | 34.17 | 51.57 | -- | 38.78 | -- | -- | -- |
| Camurus AB | 592.78m | 19.37m | 10.24bn | 170.00 | 564.07 | 15.53 | 367.67 | 17.27 | 0.4815 | 0.4815 | 15.55 | 17.49 | 0.7643 | 0.9319 | 6.59 | 5,885,939.00 | 2.50 | -27.66 | 3.09 | -33.82 | 88.13 | 86.73 | 3.27 | -84.90 | 3.03 | 47.33 | 0.0253 | -- | 78.74 | 39.49 | 45.93 | -- | 1.59 | -- |
| Zealand Pharma A/S | 100.60m | -976.09m | 10.26bn | 203.00 | -- | 25.10 | -- | 101.94 | -22.13 | -25.89 | 2.27 | 7.91 | 0.0731 | 0.1002 | 1.76 | 283,371.80 | -70.93 | -27.88 | -88.11 | -32.49 | 94.20 | -- | -970.30 | -275.48 | 3.69 | -- | 0.575 | -- | -69.28 | -14.01 | 10.84 | -- | 53.47 | -- |
| BioArctic AB | 157.13m | 18.88m | 15.59bn | 56.00 | 1,011.42 | 32.70 | 548.35 | 99.21 | 0.3075 | 0.3075 | 2.60 | 9.51 | 0.2509 | -- | -- | 4,712,408.00 | 3.01 | 5.33 | 3.31 | 7.25 | 86.75 | 87.93 | 12.01 | 24.30 | -- | -- | 0.012 | 37.21 | -62.88 | -26.18 | -74.83 | -- | 8.13 | -- |
| Bavarian Nordic A/S | 2.40bn | -599.24m | 16.67bn | 917.00 | -- | 2.39 | -- | 6.93 | -8.68 | -8.68 | 36.30 | 98.47 | 0.2146 | 2.61 | 4.96 | 3,167,704.00 | -5.35 | -2.42 | -6.74 | -2.93 | 37.85 | 45.79 | -24.92 | -11.37 | 1.71 | -1.64 | 0.3719 | -- | 2.46 | 13.52 | -267.47 | -- | 63.17 | -- |
| Vitrolife AB | 1.97bn | 239.95m | 18.71bn | 1.07k | 77.29 | 1.68 | 39.87 | 9.50 | 2.63 | 2.63 | 21.83 | 121.02 | 0.2196 | 4.01 | 8.74 | 6,775,719.00 | 2.68 | 8.88 | 2.78 | 9.55 | 55.83 | 63.53 | 12.22 | 24.08 | 1.50 | 10.92 | 0.1187 | 23.22 | 34.94 | 14.45 | 18.87 | 12.36 | 35.34 | 9.00 |
| ALK-Abello A/S | 4.36bn | 333.00m | 20.68bn | 2.60k | 67.74 | 5.71 | 35.48 | 4.74 | 1.51 | 1.51 | 19.68 | 17.87 | 0.7268 | 1.32 | 6.77 | 1,718,959.00 | 5.55 | -0.5115 | 7.21 | -0.6163 | 62.39 | 58.11 | 7.64 | -0.8118 | 1.00 | -- | 0.1419 | -- | 12.17 | 5.44 | 776.00 | -4.10 | 3.17 | -- |
Data as of Dec 06 2022. Currency figures normalised to Bavarian Nordic A/S's reporting currency: Danish Krone DKK
15.96%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Invesco Advisers, Inc.as of 31 Oct 2022 | 2.93m | 4.14% |
| The Vanguard Group, Inc.as of 04 Nov 2022 | 1.94m | 2.75% |
| Norges Bank Investment Managementas of 31 Dec 2021 | 1.72m | 2.43% |
| Dimensional Fund Advisors LPas of 04 Nov 2022 | 1.13m | 1.60% |
| BlackRock Fund Advisorsas of 03 Nov 2022 | 935.14k | 1.32% |
| Nykredit Bank A/S (Investment Management)as of 30 Sep 2022 | 697.20k | 0.99% |
| Allianz Global Investors GmbHas of 31 Jul 2022 | 522.52k | 0.74% |
| Polar Capital LLPas of 28 Oct 2022 | 505.40k | 0.72% |
| DNB Asset Management ASas of 30 Sep 2022 | 457.97k | 0.65% |
| Max Mitteregger Kapitalf�rvaltning ABas of 31 Dec 2016 | 442.44k | 0.63% |
More ▼
Data from 31 Dec 2016 - 30 Sep 2022Source: FactSet Research Systems Inc.
